Ryan Hartmaier, PhD on TATTON ctDNA: Potential Use of PFS

Ryan Hartmaier, PhD of AstraZeneca discusses TATTON (savolitinib + osimertinib) – measuring ctDNA clearance as a potential predictor of PFS in EGFRm MET-amplified NSCLC.

https://www.ascopost.com/issues/july-25-2020/ctdna-clearance-predicts-progression-free-survival-with-osimertinibsavolitinib-in-egfr-mutant-met-amplified-nsclc/